Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy

Circulation Journal

Volumn 74, Issue 11, 2010, Pages 2271-2282

  Maron, Barry J ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

Defibrillation; Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator (ICD); Sudden cardiac death

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROCAINAMIDE; QUINIDINE; VERAPAMIL;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; CULTURAL FACTOR; DEFIBRILLATOR; DEVICE INFECTION; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; GENETIC RISK; GENOTYPE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ANEURYSM; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART SURGERY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMATOMA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MEDICAL DECISION MAKING; MICROVASCULAR ISCHEMIA; PNEUMOTHORAX; PRIMARY PREVENTION; PROSTHESIS LOOSENING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; THERAPY EFFECT; VEIN THROMBOSIS;

CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HISTORY, 20TH CENTURY; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78349293794     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0921     Document Type: Review

References (69)

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20: 1-8.
2. Braunwald E, Lambrew C, Rockoff D, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. I: Description of the disease based on the analysis of 64 patients. Circulation 1964; 30(Suppl IV): 1-217.
3. Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002; 287: 1308-1320.
4. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. ACC/ESC Clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42: 1687.
5. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-2218.
6. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-1075.
7. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TG, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000; 102: 858-864.
8. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-373.
9. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405-412.
10. Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008; 19: 1118-1126.
11. Jayatilleke I, Doolan A, Ingles J, McGuire M, Booth V, Richmond DR, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004; 93: 1192-1194.
12. Woo A, Monakier D, Harris L, Hill A, Shah P, Wigle ED, et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 2007; 93: 1044-1045.
13. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 2010; 121: 445-456.
14. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26: 1887-1896.
15. Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 2010 (in press).
16. Marin F, Gimeno JR, Paya E, Garcia-Alberola A, Perez-Alverz L, Fernandez X, et al. The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy: Experience at three centers. Rev Esp Cardiol 2006; 59: 537-544.
17. Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: Efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 2010; 21: 883-889.
18. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303: 322-324.
19. Epstein AE. Benefits of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2008; 52: 1122-1127.
20. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007; 93: 708-710.
21. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655 (correction: JAMA 1999; 281: 2288).
22. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 480-487.
23. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.
24. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879.
25. Spirito P, Autore C, Rapezzi C, Bernabo P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119: 1703-1710.
26. Puntmann VO, Yap YG, McKenna W, Camm AJ. Significance of maximal and regional left ventricular wall thickness in association with arrhythmic events in patients with hypertrophic cardiomyopathy. Circ J 2010; 74: 531-537.
27. Maron MS, Finley JJ, Bos JM, Hauser RH, Manning WJ, Haas TS, et al. Prevalence, clinical significance and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118: 1541-1549.
28. Fattori R, Biagina E, Lorenzini M, Buttazzi K, Lovato L, Rapezzi C. Significance of magnetic resonance imaging in apical hypertrophic cardiomyopathy. Am J Cardiol 2010; 105: 1592-1596.
29. Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol 2009; 20: 445-447.
30. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114: 216-225.
31. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
32. Elliott PM, Gimeno JR, Tomé MT, Shah J, Ward D, Thaman R, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27: 1933-1941.
33. Efthimiadis GK, Parcharidou DG, Giannakoulas G, Pagourelias ED, Charalampidis P, Savvopoulos G, et al. Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol 2009; 104: 695-699.
34. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114: 2232-2239.
35. Maron MS, Appelbaum E, Harrigan C, Buros J, Gibson M, Hanna CA, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008; 1: 184-191.
36. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51: 1369-1374.
37. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010 [E-pub ahead of print].
38. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010 [Epub ahead of print].
39. Motoyasu M, Kurita T, Onishi K, Uemura S, Tanigawa T, Okinaka T, et al. Correlation between late gadolinium enhancement and diastolic function in hypertrophic cardiomyopathy assessed by magnetic resonance imaging. Circ J 2008; 72: 378-383.
40. Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, et al. Ventricular arrhythmia following alcohol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2009; 104: 128-132.
41. Sorajja P, Valeti U, Nishimura R, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008; 118: 131-139.
42. Cuoco FA, Spencer WH III, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52: 1718-1723.
43. tenCate F, Soliman, OII, Michels M, Theuns D, De Jong PL, Geleijnse MI, et al. Long-term outcomes of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: A word of caution. Circ Heart Fail 2010; 3: 362-369.
44. Nishimura RA, Ommen SR. Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: What statistics cannot tell you. Circ Cardiovasc Int 2010; 3: 91-93.
45. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007; 49: 350-357.
46. van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JW, Vos J, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004; 43: 27-34.
47. Maron BJ. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy [Controversies in cardiovascular medicine]. Circulation 2007; 116: 196-206.
48. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007; 28: 2583-2588.
49. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104: 2517-2524.
50. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy: Results from Kochi RYOMA Study. Circ J 2009; 73: 1599-1605.
51. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics. J Cardiovasc Electrophysiol 2008; 19: 104-110.
52. Ackerman MJ, VanDriest SL, Ommen SR, Will ML, Nishimura RA, Tajik AJ, et al. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: A comprehensive outpatient perspective. J Am Coll Cardiol 2002; 39: 2042-2048.
53. Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009; 301: 1253-1259.
54. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: Implications for genetic testing and counseling. J Med Genet 2005; 42: e59.
55. Maron BJ, Zipes DP. 36th Bethesda Conference: Eligibility recommendations for competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2005; 45: 1312-1375.
56. Maron BJ. Sudden death in hypertrophic cardiomyopathy. J Cardiovasc Trans Res 2009; 2: 368-380.
57. Maron BJ, Semsarian C, Shen WK, Link MS, Epstein AE, Estes NAM III, et al. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm 2009; 6: 599-602.
58. Przybylski A, Malecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, et al. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy: Dilemmas and difficulties. Kardiol Pol 2005; 63: 391-397.
59. Eicken A, Kolb C, Lange S, Brodherr-Heberlein S, Zrenner B, Schreiber C, et al. Implantable cardioverter defibrillator (ICD) in children. Int J Cardiol 2006; 107: 30-35.
60. Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, et al. Implantable cardioverter-defibrillators in hypertrophic cardiomypathy. Rev Port Cardiol 2005; 24: 407-415.
61. Kaski JP, Esteban MTT, Lowe M, Sporton S, Rees P, Deanfield JE, et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 2007; 93: 372-374.
62. Lin G, Nishimura RA, Gersh BJ, Ommen S, Ackerman M, Brady PA. Device complications and inappropriate implantable cardioverter- defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009; 95: 709-714.
63. Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, et al. Results of a multicenter retrospective implantable cardioverter- defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008; 51: 1685-1691.
64. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54: 220-228.
65. Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 866-875.
66. Hauser RG, Maron BJ. Lessons from the failure and defibrillator. Circulation 2005; 112: 2040-2042.
67. Maron BJ, Haas TS, Shannon KM. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm 2009; 6: 993-997.
68. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008; 52: 1111-1121.
69. Hauser RG, Kallinen LM, Almquist AK, Gornick CC, Katsiyiannis WT. Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm 2007; 4: 892-896.